{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/ELOX/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-08T05:51:47.786Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":53,"canonical_name":"Eloxx Pharmaceuticals, Inc.","cik":"0001035354","uei":null,"lei":null,"duns":null,"ticker":"ELOX"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":33,"clinical":1},"count":34,"timeline":[{"ts":"2026-09-11","kind":"sec.filing","form_type":"S-1","title":"S-1 — Eloxx Pharmaceuticals, Inc. — 2026-09-11","url_slug":"/sec/cik-0001035354/s-1/0001193125-26-389422","accession_number":"0001193125-26-389422","importance":65},{"ts":"2026-08-11","kind":"sec.filing","form_type":"10-Q","title":"10-Q — Eloxx Pharmaceuticals, Inc. — 2026-08-11","url_slug":"/sec/cik-0001035354/10-q/0001193125-26-344964","accession_number":"0001193125-26-344964","importance":45},{"ts":"2026-08-11","kind":"sec.filing","form_type":"8-K","title":"8-K — Eloxx Pharmaceuticals, Inc. — 2026-08-11","url_slug":"/sec/cik-0001035354/8-k/0001193125-26-345032","accession_number":"0001193125-26-345032","importance":35},{"ts":"2026-06-17","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Eloxx Pharmaceuticals, Inc. — 2026-06-17","url_slug":"/sec/cik-0001035354/schedule-13g/0000919574-26-004022","accession_number":"0000919574-26-004022","importance":55},{"ts":"2026-06-17","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Eloxx Pharmaceuticals, Inc. — 2026-06-17","url_slug":"/sec/cik-0001035354/schedule-13g/0001104659-26-075290","accession_number":"0001104659-26-075290","importance":55},{"ts":"2026-06-17","kind":"sec.filing","form_type":"3","title":"3 — Eloxx Pharmaceuticals, Inc. — 2026-06-17","url_slug":"/sec/cik-0001035354/3/0000919574-26-004020","accession_number":"0000919574-26-004020","importance":30},{"ts":"2026-06-17","kind":"sec.filing","form_type":"4","title":"4 — Eloxx Pharmaceuticals, Inc. — 2026-06-17","url_slug":"/sec/cik-0001035354/4/0000919574-26-004021","accession_number":"0000919574-26-004021","importance":30},{"ts":"2026-06-16","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Eloxx Pharmaceuticals, Inc. — 2026-06-16","url_slug":"/sec/cik-0001035354/schedule-13g/0000935836-26-000321","accession_number":"0000935836-26-000321","importance":55},{"ts":"2026-06-16","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Eloxx Pharmaceuticals, Inc. — 2026-06-16","url_slug":"/sec/cik-0001035354/schedule-13g/0001440771-26-000006","accession_number":"0001440771-26-000006","importance":55},{"ts":"2026-06-15","kind":"sec.filing","form_type":"SCHEDULE 13G","title":"SCHEDULE 13G — Eloxx Pharmaceuticals, Inc. — 2026-06-15","url_slug":"/sec/cik-0001035354/schedule-13g/0002005369-26-000037","accession_number":"0002005369-26-000037","importance":55},{"ts":"2026-06-10","kind":"sec.filing","form_type":"4","title":"4 — Eloxx Pharmaceuticals, Inc. — 2026-06-10","url_slug":"/sec/cik-0001035354/4/0001193125-26-266275","accession_number":"0001193125-26-266275","importance":30},{"ts":"2026-06-10","kind":"sec.filing","form_type":"4","title":"4 — Eloxx Pharmaceuticals, Inc. — 2026-06-10","url_slug":"/sec/cik-0001035354/4/0001193125-26-266276","accession_number":"0001193125-26-266276","importance":30},{"ts":"2026-06-10","kind":"sec.filing","form_type":"4","title":"4 — Eloxx Pharmaceuticals, Inc. — 2026-06-10","url_slug":"/sec/cik-0001035354/4/0001193125-26-266277","accession_number":"0001193125-26-266277","importance":30},{"ts":"2026-06-10","kind":"sec.filing","form_type":"4","title":"4 — Eloxx Pharmaceuticals, Inc. — 2026-06-10","url_slug":"/sec/cik-0001035354/4/0001193125-26-266278","accession_number":"0001193125-26-266278","importance":30},{"ts":"2026-06-10","kind":"sec.filing","form_type":"4","title":"4 — Eloxx Pharmaceuticals, Inc. — 2026-06-10","url_slug":"/sec/cik-0001035354/4/0001193125-26-266279","accession_number":"0001193125-26-266279","importance":30},{"ts":"2026-06-10","kind":"sec.insider.j","reporter":"Domicilium Real Estate Fund III LP","title":"","shares":238422,"price_per_share":null,"usd_value":0,"security_title":"common stock, $0.01 par value per share","importance":15},{"ts":"2026-06-10","kind":"sec.insider.j","reporter":"Domicilium Real Estate Fund III LP","title":"","shares":361578,"price_per_share":null,"usd_value":0,"security_title":"common stock, $0.01 par value per share","importance":15},{"ts":"2026-06-09","kind":"sec.filing","form_type":"424B4","title":"424B4 — Eloxx Pharmaceuticals, Inc. — 2026-06-09","url_slug":"/sec/cik-0001035354/424b4/0001193125-26-263914","accession_number":"0001193125-26-263914","importance":55},{"ts":"2026-06-08","kind":"sec.filing","form_type":"CERT","title":"CERT — Eloxx Pharmaceuticals, Inc. — 2026-06-08","url_slug":"/sec/cik-0001035354/cert/0001354457-26-000547","accession_number":"0001354457-26-000547","importance":30},{"ts":"2026-06-08","kind":"sec.filing","form_type":"EFFECT","title":"EFFECT — Eloxx Pharmaceuticals, Inc. — 2026-06-08","url_slug":"/sec/cik-0001035354/effect/9999999995-26-001918","accession_number":"9999999995-26-001918","importance":30},{"ts":"2026-06-05","kind":"sec.filing","form_type":"4","title":"4 — Eloxx Pharmaceuticals, Inc. — 2026-06-05","url_slug":"/sec/cik-0001035354/4/0000919574-26-003845","accession_number":"0000919574-26-003845","importance":30},{"ts":"2026-06-05","kind":"sec.filing","form_type":"SCHEDULE 13G/A","title":"SCHEDULE 13G/A — Eloxx Pharmaceuticals, Inc. — 2026-06-05","url_slug":"/sec/cik-0001035354/schedule-13g-a/0000919574-26-003846","accession_number":"0000919574-26-003846","importance":30},{"ts":"2026-06-04","kind":"sec.filing","form_type":"S-1/A","title":"S-1/A — Eloxx Pharmaceuticals, Inc. — 2026-06-04","url_slug":"/sec/cik-0001035354/s-1-a/0001193125-26-257750","accession_number":"0001193125-26-257750","importance":30},{"ts":"2026-06-01","kind":"sec.filing","form_type":"8-K","title":"8-K — Eloxx Pharmaceuticals, Inc. — 2026-06-01","url_slug":"/sec/cik-0001035354/8-k/0001193125-26-249692","accession_number":"0001193125-26-249692","importance":35},{"ts":"2026-06-01","kind":"sec.filing","form_type":"3","title":"3 — Eloxx Pharmaceuticals, Inc. — 2026-06-01","url_slug":"/sec/cik-0001035354/3/0001193125-26-249689","accession_number":"0001193125-26-249689","importance":30},{"ts":"2026-06-01","kind":"sec.filing","form_type":"3","title":"3 — Eloxx Pharmaceuticals, Inc. — 2026-06-01","url_slug":"/sec/cik-0001035354/3/0001193125-26-249690","accession_number":"0001193125-26-249690","importance":30},{"ts":"2026-06-01","kind":"sec.filing","form_type":"8-A12B","title":"8-A12B — Eloxx Pharmaceuticals, Inc. — 2026-06-01","url_slug":"/sec/cik-0001035354/8-a12b/0001193125-26-251780","accession_number":"0001193125-26-251780","importance":30},{"ts":"2026-06-01","kind":"sec.filing","form_type":"S-1/A","title":"S-1/A — Eloxx Pharmaceuticals, Inc. — 2026-06-01","url_slug":"/sec/cik-0001035354/s-1-a/0001193125-26-251655","accession_number":"0001193125-26-251655","importance":30},{"ts":"2026-05-27","kind":"sec.insider.j","reporter":"Domicilium Real Estate Fund III LP","title":"","shares":113636,"price_per_share":0,"usd_value":0,"security_title":"Common Stock, $0.01 par value per share","importance":15},{"ts":"2026-05-08","kind":"sec.filing","form_type":"4","title":"4 — Eloxx Pharmaceuticals, Inc. — 2026-05-08","url_slug":"/sec/cik-0001035354/4/0001193125-26-214815","accession_number":"0001193125-26-214815","importance":30},{"ts":"2026-05-08","kind":"sec.filing","form_type":"4","title":"4 — Eloxx Pharmaceuticals, Inc. — 2026-05-08","url_slug":"/sec/cik-0001035354/4/0001193125-26-214890","accession_number":"0001193125-26-214890","importance":30},{"ts":"2026-05-08","kind":"sec.filing","form_type":"4","title":"4 — Eloxx Pharmaceuticals, Inc. — 2026-05-08","url_slug":"/sec/cik-0001035354/4/0001193125-26-214983","accession_number":"0001193125-26-214983","importance":30},{"ts":"2026-05-08","kind":"sec.filing","form_type":"DEF 14C","title":"DEF 14C — Eloxx Pharmaceuticals, Inc. — 2026-05-08","url_slug":"/sec/cik-0001035354/def-14c/0001193125-26-214720","accession_number":"0001193125-26-214720","importance":30},{"ts":"2026-04-13","kind":"clinical.trial","reporter":"Eloxx Pharmaceuticals, Inc.","title":"EXACT Study: A Blinded Study in Patients With Alport Syndrome to Evaluate Exaluren Efficacy and Safety","security_title":"PHASE2","status":"NOT_YET_RECRUITING","accession_number":"NCT07523581","excerpt":"[\"Alport Syndrome, X-Linked\",\"Alport Syndrome, Autosomal Recessive\"]","importance":45}]}